Cytokinetics, Incorporated announced that the European Commission has approved its cardiac myosin inhibitor MYQORZO (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. The approval, effective February 17, 2026, allows the company to launch the drug in the European Union, beginning with a first commercial launch in Germany in the second quarter of 2026.
The decision was based on the positive results of the Phase 3 SEQUOIA‑HCM trial, which demonstrated significant improvements in exercise capacity, symptom relief, and hemodynamic parameters compared with placebo. In the 24‑week study, patients treated with MYQORZO showed an increase in peak oxygen uptake of 1.76 mL/kg/min versus no improvement in the placebo group, underscoring the drug’s clinical benefit.
The approval expands MYQORZO’s addressable market to an estimated 300,000–400,000 adults with oHCM across the EU, a substantial portion of the global HCM patient population. It also positions the drug to compete directly with Bristol‑Myers Squibb’s Camzyos, the first cardiac myosin inhibitor approved in the United States, thereby strengthening Cytokinetics’ competitive standing in the niche cardiovascular market.
Cytokinetics’ recent financial results provide context for the approval’s impact. In Q1 2025 the company reported a net loss of $1.36 per share, narrower than the consensus estimate of a $1.41 loss, and revenue of $1.6 million, up from $0.8 million in the same period a year earlier. R&D expenses rose 22.4% year‑over‑year to $99.8 million, driven by advancing clinical trials and higher personnel costs, while G&A expenses increased 26.1% to $57.4 million due to commercial readiness investments and personnel costs.
Robert I. Blum, Cytokinetics’ President and Chief Executive Officer, said the approval “is an important milestone toward bringing this medicine to more patients living with obstructive HCM around the world.” He added that the European label “allows providers flexibility to determine whether a patient starts treatment at either 5 mg or 10 mg, based on the severity of their baseline LVOT obstruction,” and that the company looks forward to making MYQORZO available in Europe, beginning with Germany in the second quarter of the year.
Analysts noted the approval as a key de‑risking event that could accelerate reimbursement negotiations and broaden the company’s commercial footprint. The regulatory milestone also signals confidence in Cytokinetics’ muscle‑modulator platform and may facilitate future approvals for its other cardiac and skeletal muscle programs.
The EU approval is expected to accelerate the company’s revenue trajectory by opening a new market and providing a platform for future product launches. It also enhances Cytokinetics’ ability to negotiate reimbursement with European payers, leveraging the robust clinical data from the SEQUOIA‑HCM trial. The approval validates the company’s regulatory strategy and may accelerate future approvals for its other cardiac and skeletal muscle programs.
In summary, the European Commission’s approval of MYQORZO marks a pivotal moment for Cytokinetics, expanding its market reach, strengthening its competitive position, and setting the stage for future growth in the cardiovascular therapeutics space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.